Pfizer, Merck KGaA clinch needed approval for Bavencio, directly competing against Keytruda in kidney cancer

Less than a month after Merck notched an early OK to market a Keytruda combo as frontline therapy for renal cell carcinoma, rivals Pfizer and Merck KGaA have arrived at the scene with its own FDA approval.

As is the case with Keytruda, their PD-L1 inhibitor Bavencio is sanctioned for use with Inlyta, a tyrosine kinase inhibitor from Pfizer. In the Phase III JAVELIN Renal 101 study, this combo demonstrated a significant progression-free survival benefit: five months across the intent-to-treat patient population compared to the comparator arm, who were given Sutent. That surpassed the expectations of investigators as they initially narrowed the focus to PD-L1 positive patients.

In order to read this article, you must be an Endpoints News subscriber. (It's free to subscribe.)

← Go back

We produce two daily email newsletters designed to give you a complete picture of what's important in biopharma. It's free to subscribe and never any spam. Join 51,200+ biopharma executives who read Endpoints News every day.

Access is subject to the terms in our Privacy Policy.

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 51,200+ biopharma pros who read Endpoints News by email every day.

Free Subscription

VP Oncology Biology
Skyhawk Therapeutics Waltham, MA
Associate Director CMC
Elektroki Boston, MA
Director Process Development
Elektroki Boston, MA
Research Scientist - Immunology
Recursion Pharmaceuticals Salt Lake City, UT

Visit Endpoints Careers ->